Zhou Zhaokai, Xu Jiaxin, Liu Shutong, Lv Yingying, Zhang Ruiqi, Zhou Xing, Zhang Yuyuan, Weng Siyuan, Xu Hui, Ba Yuhao, Zuo Anning, Han Xinwei, Liu Zaoqu
Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China.
Department of Urology, The First Affiliated Hospital of Zhengzhou University, Henan, 450052, China.
Biomark Res. 2024 Sep 4;12(1):97. doi: 10.1186/s40364-024-00630-9.
Immunotherapy has shown promising anti-tumor effects across various tumors, yet it encounters challenges from the inhibitory tumor immune microenvironment (TIME). Infiltrating regulatory T cells (Tregs) are important contributors to immunosuppressive TIME, limiting tumor immunosurveillance and blocking effective anti-tumor immune responses. Although depletion or inhibition of systemic Tregs enhances the anti-tumor immunity, autoimmune sequelae have diminished expectations for the approach. Herein, we summarize emerging strategies, specifically targeting tumor-infiltrating (TI)-Tregs, that elevate the capacity of organisms to resist tumors by reprogramming their phenotype. The regulatory mechanisms of Treg reprogramming are also discussed as well as how this knowledge could be utilized to develop novel and effective cancer immunotherapies.
免疫疗法已在多种肿瘤中显示出有前景的抗肿瘤效果，但它面临着来自抑制性肿瘤免疫微环境（TIME）的挑战。浸润性调节性T细胞（Tregs）是免疫抑制性TIME的重要促成因素，限制了肿瘤免疫监视并阻断有效的抗肿瘤免疫反应。尽管全身性Tregs的耗竭或抑制可增强抗肿瘤免疫力，但自身免疫后遗症降低了对该方法的期望。在此，我们总结了新兴策略，特别是针对肿瘤浸润（TI）-Tregs的策略，这些策略通过重新编程其表型来提高生物体抵抗肿瘤的能力。还讨论了Treg重编程的调节机制，以及如何利用这些知识开发新型有效的癌症免疫疗法。
